Skip to main content

Advertisement

Table 1 Clinical characteristics of the head and neck squamous cell carcinoma cohort

From: Cell-in-cell structures are more potent predictors of outcome than senescence or apoptosis in head and neck squamous cell carcinomas

169 patients with available pre-RCT biopsies
Gender
 Male 140 (82.8%)
 Female 29 (17.2%)
Age <56.4: 85 (50.3%) >56.4: 84 (49.7%)
T-Stage
 T1 38 (24.2%)
 T2 58 (36.9%)
 T3 29 (18.5%)
 T4 32 (20.4%)
N-Stage
 N0 33 (21%)
 N1 48 (30.6%)
 N2 69 (43.9%)
 N3 7 (4.5%)
M-Stage
 M0 132 (98.5%)
 M1 2 (1.5%)
Grading
 G1 9 (5.7%)
 G2 90 (56.6%)
 G3 60 (37.7%)
Localization of tumor
 Oropharynx 83 (49.1%)
 Base of the mouth 79 (46.8%)
 Alveolar ridge 7 (4.1%)
Radiotherapy
 Neoadjuvant 32 (18.9%)
 Adjuvant 137 (81.1%)
Mean total dose 59.2 Grey
Mean dose per fraction 2.0 Grey
Chemotherapy
 None 49 (29%)
 5-FU + Cisplatin 93 (55%)
 5-FU + Carboplatin 9 (5.3%)
 Others 18 (10.7%)
32 patients with available post-RCT biopsies
Gender
 Male 28 (87.5%)
 Female 4 (12.5%)
Age <51.4: 71 (46.4%) >51.4: 82 (53.6%)
T-stage
 T1 2 (6.3%)
 T2 10 (31.2%)
 T3 8 (25%)
 T4 12 (37.5%)
N-Stage
 N0 11 (34.4%)
 N1 21 (65.6%)
M-Stage
 M0 32 (100%)
Grading
 G1 1 (3.7%)
 G2 21 (77.8%)
 G3 5 (18.5%)
Localization of tumor
 Oropharynx 8 (25.0%)
 Base of the mouth 23 (71.9%)
 Alveolar ridge 1 (3.1%)
Radiotherapy
 Neoadjuvant 32 (100%)
Mean total dose 50.1 Grey
Mean dose per fraction 1.8 Grey
Chemotherapy
 None 1 (3.1%)
 5-FU + Cisplatin 29 (90.6%)
 5-FU + Carboplatin 2 (6.3%)